BioSpace News Archive

Fore Biotherapeutics announced the presentation of new data demonstrating that FORE8394, a next-generation BRAF inhibitor, provides evidence of durable anti-tumor activity and patient benefit in BRAF-mutated (V600+) cancers.

Arbor Biotechnologies announced that Fierce Biotech has named it as one of 2022’s “Fierce 15” biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry.

Selecta Biosciences, Inc.announced that Company’s Management will participate in upcoming investor conferences in September.

Heska Corporation announced that the Company has entered a definitive agreement to acquire 100% of the share capital of MBio Diagnostics, Inc. d/b/a LightDeck Diagnostics, a pioneer in innovative planar waveguide fluorescence immunoassay diagnostics with strong manufacturing and specialized production capabilities.

Chiesi Global Rare Diseases announced today that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) and granted Priority Review designation for velmanase alfa, the company’s investigational enzyme replacement therapy for the proposed treatment of alpha-mannosidosis.

Neurolens, a company commercializing innovative solutions to optimize vision, announced completion of a $67 million financing.

Johnson & Johnson Vision Care, Inc. announced the launch of its newest innovation, ACUVUE® OASYS MAX 1-DAY contact lenses and ACUVUE® OASYS MAX 1-Day MULTIFOCAL contact lenses for presbyopia.

UroGen Pharma Ltd. today announced the appointment of Dr. Leana S. Wen to its Board of Directors, effective immediately.

Synthekine Inc. , an engineered cytokine therapeutics company, today announced that Fierce Biotech has named it as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry.

Ra Medical Systems, Inc. (NYSE American: RMED) (“Ra Medical” or the “Company”) announces it has entered into an Agreement and Plan of Merger (the “Definitive Merger Agreement”) with privately held Catheter Precision, Inc. (“Catheter Precision”), a medical device and technology company focused in the field of cardiac electrophysiology.